Vaccination clinic begins Tuesday at MD Anderson
Following receipt of the Pfizer COVID-19 vaccine on Monday morning, MD Anderson’s Pharmacy, Infection Control, Employee Health and clinical and facilities experts re-reviewed protocols and procedures, and an initial vaccination clinic simulation was completed. Based on those successful efforts along with a manager briefing and employee town hall, positive feedback from managers about employee engagement and swift uptake of appointment...
MD Anderson researcher elected to ASCO Board of Directors
Mariana Chavez Mac Gregor, M.D., M.Sc., associate professor in Health Services Research with a joint appointment in Breast Medical Oncology...
COVID-19 vaccine delivery and distribution statement from MD Anderson
The University of Texas MD Anderson Cancer Center is prepared to accept, store and distribute the Pfizer COVID-19 vaccine following the Food...
Combination of chemotherapy and blinatumomab improves survival for patients with B-cell acute lymphoblastic leukemia
ABSTRACT 464
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative...
CAR T cell therapy effective as first-line treatment for high-risk large B-cell lymphoma
ABSTRACT 405
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19...
Novel antibody-drug conjugate shows promising early results in rare blood cancer
ABSTRACT 167
A phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center found IMGN632, a novel CD123...